ClinicalTrials.gg
CompletedNCT03842839Updated Oct 21, 2026

Effect of Tiotropium on Airway Remodeling in Patients With Early Stage COPD Accessed by Optical Coherence Tomography

An interventional study of Tiotropium Inhalation Powder [Spiriva] 0.018mg and Salbutamol sulphate aerosol (Ventolin) 0.1mg in Airway Remodeling and Chronic Obstructive Pulmonary Disease, sponsored by Guangzhou Institute of Respiratory Disease. Completed at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Guangzhou Institute of Respiratory Disease · Not applicable, Interventional, and Treatment

How we know

Updated Oct 21, 2026Now CompletedStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

This randomized, open-label, three-arm clinical trial evaluated the effects of tiotropium on airway remodeling in patients with GOLD stage 1 COPD using endobronchial optical coherence tomography (EB-OCT). Participants were randomly assigned to receive tiotropium for 12 months followed by withdrawal for months 12-24, tiotropium continuously for 24 months, or SABA as needed without regular long-acting bronchodilator therapy. Airway morphology, pulmonary function, impulse oscillometry, and SABA use were assessed during the 24-month follow-up.

02

Conditions studied

  • Airway Remodeling
  • Chronic Obstructive Pulmonary Disease

Keywords

  • Tiotropium
  • Endobronchial Optical Coherence Tomography
  • GOLD 1 COPD
  • Airway Morphology
  • Small Airways
03

In context

Airway Remodeling

28 studies on the registry are indexed under Airway Remodeling; 5 are open to participants now.

This study's enrollment of 84 is above the median of 40 across 21 interventional studies indexed under Airway Remodeling.

Browse Airway Remodeling studies →

Lead sponsor

Guangzhou Institute of Respiratory Disease is the lead sponsor of 99 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria

  • Over 40 yrs; Male or female Diagnosed with
  • Post-bronchodilator /FVC \<0.70 and FEV1 ≥80% predicted;
  • Patients must be able to perform all study related procedures

Exclusion Criteria:

  • Patients with other lung diseases (such as bronchiectasis, pneumothorax, pleural effusion, airway deformation, lung surgery, etc.).
  • Patients have poor compliance and are unwilling to receive medication regularly.
  • Other complications of bronchoscopy or intolerance of bronchoscopy procedure.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Tiotropium (0-12 month) + SABA as needed

    * During the 2 years treatment phase patients will be administered with tiotropium bromide (Spiriva) capsule 18μg once daily from baseline to the 12th months. * Scheduled tiotropium treatment was discontinued after month 12. Additional maintenance inhaled therapy was permitted if clinically indicated and was recorded. * Salbutamol sulphate aerosol (Ventolin) was available as needed for symptom relief throughout the 24-month follow-up.

    Drug: Tiotropium Inhalation Powder [Spiriva] 0.018mg · Drug: Salbutamol sulphate aerosol (Ventolin) 0.1mg

  • Experimental
    Tiotropium (0-24 month) + SABA as needed

    * During the 2 years treatment phase patients will be administered with tiotropium bromide (Spiriva) capsule 18μg once daily from baseline to the 24th months. * Salbutamol sulphate aerosol (Ventolin) was available as needed for symptom relief throughout the 24-month follow-up.

    Drug: Tiotropium Inhalation Powder [Spiriva] 0.018mg · Drug: Salbutamol sulphate aerosol (Ventolin) 0.1mg

  • Other
    SABA as needed only

    * During the 24-month study period, salbutamol inhalation aerosol (Ventolin) was available as needed for symptom relief. * No scheduled long-acting bronchodilator was assigned in this group. Additional maintenance inhaled therapy was permitted if clinically indicated and was recorded.

    Drug: Salbutamol sulphate aerosol (Ventolin) 0.1mg

Interventions

  • DrugTiotropiumStudies of TiotropiumTiotropium pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tiotropium bromide (Spiriva) capsule 18μg once daily inhaled.

    Also known as: Spiriva

  • DrugAlbuterolStudies of AlbuterolAlbuterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Salbutamol inhalation aerosol (Ventolin), 100 μg per actuation, was available as needed for symptom relief throughout the 24-month study period.

    Also known as: Ventolin

06

What researchers measure

Primary outcomes

  1. Change from baseline in inner luminal area (Ai) of small airways (7th to 9th generation bronchi) at month 24

    To evaluate the effects of tiotropium on structural remodeling of small airways in patients with early-stage COPD.

    Time frame: Baseline and month 24

Secondary outcomes

  1. Change from baseline in inner luminal area (Ai) of small airways (7th to 9th generation bronchi) at month 12

    Change from baseline to month 12 in patient-level mean airway luminal area of generations 7-9, measured by EB-OCT (mm²).

    Time frame: Baseline and Month 12

  2. Change from baseline in inner luminal area (Ai) of 3rd-6th generation bronchi

    To evaluate the effects of tiotropium on structural remodeling of medium-sized airways in patients with early-stage COPD.

    Time frame: Baseline, Month 12, and Month 24

  3. Change from baseline in the airway wall area percentage (Aw%) of the 7th to 9th generation bronchi

    To evaluate the effects of Tiotropium in ameliorating airway remodeling in early stage COPD

    Time frame: Baseline, Month 12, and Month 24

  4. Change from baseline in the airway wall area percentage (Aw%) of the 3rd to 6th generation bronchi

    To evaluate the effects of Tiotropium in ameliorating airway remodeling in early stage COPD

    Time frame: Baseline, Month 12, and Month 24

  5. Change from baseline in trough FEV1

    To evaluate the effects of Tiotropium in improving lung function

    Time frame: Baseline, Month 12, and Month 24

  6. Change from baseline in peripheral airway resistance (R5-R20)

    To evaluate the effects of Tiotropium in improving lung function

    Time frame: Baseline, Month 12, and Month 24

  7. Change from baseline in COPD Assessment Test (CAT) score

    Change from baseline in COPD Assessment Test (CAT) score

    Time frame: Baseline, Month 12, and Month 24

Other outcomes

  1. Changes from baseline in parametric response mapping-defined functional small-airway disease and emphysema

    Changes from baseline in parametric response mapping-defined functional small-airway disease and emphysema

    Time frame: Baseline, month 12 and month 24

  2. Proportion of participants experiencing at least one COPD exacerbation during 24 months

    Proportion of participants experiencing at least one COPD exacerbation during the 24-month follow-up.

    Time frame: Baseline to Month 24

07

Study locations

1 site
  • Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data underlying the published results may be shared upon reasonable request, subject to institutional approval, applicable consent restrictions, and a data-use agreement.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Deidentified participant-level data will be available upon reasonable request for five years following publication of the primary study results, subject to institutional approval and applicable data retention policies.

Access criteria: Requests should be directed to the corresponding author. Access will be considered for scientifically justified research proposals, subject to institutional approval, applicable consent restrictions, and execution of an appropriate data-use agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2019 to primary completion in May 2025, 69 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Oct 2018 → Aug 2019, primary completion Dec 2022 → May 2025 and completion Dec 2022 → May 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2019
First posted
Feb 15, 2019
StartActual
Aug 1, 2019was Oct 2018
Primary completionActual
May 7, 2025was Dec 2022
CompletionActual
May 7, 2025was Dec 2022
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 21, 2026
Start date
Oct 1, 2018→Aug 1, 2019
Oct 21, 2026
Primary completion
Dec 2022→May 7, 2025 (actual)
Oct 21, 2026
Study completion
Dec 2022→May 7, 2025 (actual)
Oct 21, 2026
Enrollment
100 (estimated)→84 (actual)
Oct 21, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • EditedPrePost-bronchodilator FEV1/FVC <0.70 and FEV1 ≥80% pred predicted;
Oct 21, 2026
Interventions
Changed Salbutamol sulphate aerosol (Ventolin) 0.01mg→Salbutamol sulphate aerosol (Ventolin) 0.1mg
Oct 21, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedChange from baseline in the inner luminal area (Ai) of the 3thsmall airways (7th to 9th generation bronchi) at month 24Time frame: Ai accessed by endobronchial optical coherence tomography will be obtained at baseline, month 24. → Baseline and month 24
  • RemovedChange from baseline in the inner luminal area (Ai) of the 3th to 9th generation bronchi at month 12Time frame: Ai accessed by endobronchial optical coherence tomography will be obtained at month 12.
Oct 21, 2026
Secondary outcomes
2 edited, 2 time frame changed, 5 added, 3 removed
What changed in the outcomes
  • EditedChange from baseline in the airway wallinner luminal area percentage (Aw%Ai) of the 3thsmall airways (7th to 9th generation bronchi) at month 12Time frame: Aw% accessed by endobronchial optical coherence tomography will be obtained at baseline, month 12. → Baseline and Month 12
  • EditedChange from baseline in the airway wallinner luminal area percentage (Aw%Ai) of the 3th to 9th3rd-6th generation bronchi at month 24Time frame: Aw% accessed by endobronchial optical coherence tomography will be obtained at month24. → Baseline, Month 12, and Month 24
  • AddedChange from baseline in the airway wall area percentage (Aw%) of the 7th to 9th generation bronchiTime frame: Baseline, Month 12, and Month 24
  • AddedChange from baseline in the airway wall area percentage (Aw%) of the 3rd to 6th generation bronchiTime frame: Baseline, Month 12, and Month 24
  • AddedChange from baseline in COPD Assessment Test (CAT) scoreTime frame: Baseline, Month 12, and Month 24
  • RemovedChange from baseline in resonant frequency (Fres) at month 6, 12, 18 and 24.Time frame: IOS will be performed at baseline, month 6, 12, 18 and 24.
  • RemovedTotal times of SABA usageTime frame: During the two years treatment period, times of SABA administration will be recored.
  • RemovedTotal dosage of SABA usageTime frame: During the two years treatment period, the dosage of SABA administration will be recored.
  • Time frameChange from baseline in trough FEV1Pulmonary function test will be performed at baseline, month 6, 12, 18 and 24. → Baseline, Month 12, and Month 24
  • Time frameChange from baseline in peripheral airway resistance (R5-R20)IOS will be performed at baseline, month 6, 12, 18 and 24. → Baseline, Month 12, and Month 24
  • Addedother outcomeChanges from baseline in parametric response mapping-defined functional small-airway disease and emphysemaTime frame: Baseline, month 12 and month 24
  • Addedother outcomeProportion of participants experiencing at least one COPD exacerbation during 24 monthsTime frame: Baseline to Month 24
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Status unknown→Completed
    Start date Oct 1, 2018→Aug 1, 2019
    Primary completion Dec 2022→May 7, 2025 (now actual)
    Study completion Dec 2022→May 7, 2025 (now actual)
    Enrollment 100 (estimated)→84 (actual)
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedPrePost-bronchodilator FEV1/FVC <0.70 and FEV1 ≥80% pred predicted;
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedChange from baseline in the inner luminal area (Ai) of the 3thsmall airways (7th to 9th generation bronchi) at month 24Time frame: Ai accessed by endobronchial optical coherence tomography will be obtained at baseline, month 24. → Baseline and month 24
    • RemovedChange from baseline in the inner luminal area (Ai) of the 3th to 9th generation bronchi at month 12Time frame: Ai accessed by endobronchial optical coherence tomography will be obtained at month 12.
    Secondary outcomes 2 edited, 2 time frame changed, 5 added, 3 removed
    What changed in the outcomes
    • EditedChange from baseline in the airway wallinner luminal area percentage (Aw%Ai) of the 3thsmall airways (7th to 9th generation bronchi) at month 12Time frame: Aw% accessed by endobronchial optical coherence tomography will be obtained at baseline, month 12. → Baseline and Month 12
    • EditedChange from baseline in the airway wallinner luminal area percentage (Aw%Ai) of the 3th to 9th3rd-6th generation bronchi at month 24Time frame: Aw% accessed by endobronchial optical coherence tomography will be obtained at month24. → Baseline, Month 12, and Month 24
    • AddedChange from baseline in the airway wall area percentage (Aw%) of the 7th to 9th generation bronchiTime frame: Baseline, Month 12, and Month 24
    • AddedChange from baseline in the airway wall area percentage (Aw%) of the 3rd to 6th generation bronchiTime frame: Baseline, Month 12, and Month 24
    • AddedChange from baseline in COPD Assessment Test (CAT) scoreTime frame: Baseline, Month 12, and Month 24
    • RemovedChange from baseline in resonant frequency (Fres) at month 6, 12, 18 and 24.Time frame: IOS will be performed at baseline, month 6, 12, 18 and 24.
    • RemovedTotal times of SABA usageTime frame: During the two years treatment period, times of SABA administration will be recored.
    • RemovedTotal dosage of SABA usageTime frame: During the two years treatment period, the dosage of SABA administration will be recored.
    • Time frameChange from baseline in trough FEV1Pulmonary function test will be performed at baseline, month 6, 12, 18 and 24. → Baseline, Month 12, and Month 24
    • Time frameChange from baseline in peripheral airway resistance (R5-R20)IOS will be performed at baseline, month 6, 12, 18 and 24. → Baseline, Month 12, and Month 24
    • Addedother outcomeChanges from baseline in parametric response mapping-defined functional small-airway disease and emphysemaTime frame: Baseline, month 12 and month 24
    • Addedother outcomeProportion of participants experiencing at least one COPD exacerbation during 24 monthsTime frame: Baseline to Month 24
    Interventions Changed Salbutamol sulphate aerosol (Ventolin) 0.01mg→Salbutamol sulphate aerosol (Ventolin) 0.1mg
    + 7 other changes: verification date, description, conditions, site details, contact details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03842839
Lead sponsor
Guangzhou Institute of Respiratory Disease
Responsible party
ShiYue Li (Professor, Guangzhou Institute of Respiratory Disease) — Principal investigator
First posted
Feb 15, 2019
Start date
Aug 1, 2019
Primary completion
May 7, 2025
Completion
May 7, 2025
Last update
Oct 21, 2026

Study contacts

Shiyue Li, MD
principal investigator · Guangzhou Institute of Respiratory Health

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tiotropium

Start the discussion